A FLOW CYTOMETRY-BASED LYMPOCYTE TEST FOR IMPROVED DETECT OF BERYLLIUM HYPERSEN

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。慢性铍中毒是由对吸入铍的免疫反应引起的，发生在1%到5%的铍工人中。CBD的一个重要特征是对铍过敏。通常使用从外周血样品中分离的淋巴细胞和胸苷掺入在体外测定贝伐他汀超敏反应。我们已经开发了一种流式细胞术分析血液淋巴细胞亚群增殖反应的挑战与可溶性铍。该测试，称为免疫LPT（淋巴细胞增殖测试）结合BrDU吸收或细胞周期分析与免疫表型在同一个分析。铍敏感性的主要目标是CD 4+细胞群。免疫LPT已经。已经使用来自诊断患有慢性乳腺炎的患者的外周血样品进行了验证。与环境安全和健康司合作，正在应用免疫LPT筛查LANL铍工人队列和DOE系统中的其他铍工人队列对铍过敏。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic Beryllium Disease is caused by an immune response to inhaled beryllium, and occurs in 1 to 5% of the beryllium worker population. A critical feature of CBD is hypersensitivity to beryllium. Beryllium hypersensitivity is typically assayed in vitro using lymphocytes isolated from peripheral blood samples and thymidine incorporation. We have developed a flow cytometry assay for the analysis of blood lymphocyte subset proliferation in response to a challenge with soluble beryllium. The test, called the Immuno-LPT (Lymphocyte Proliferation Test) combines BrDU uptake or cell cycle analysis with immunophenotyping in the same assay. The primary target for beryllium sensitivity is the CD4+ cell population. The Immuno-LPT has been. has been validated using peripheral blood samples from patients diagnosed with Chronic Beryllium Disease. In collaboration with Environmental Safety and Health Division, the Immuno-LPT is being applied to screen the LANL beryllium worker cohort and other beryllium worker cohorts in the DOE system for hypersensitivity to beryllium.